英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
85332查看　85332　在百度字典中的解释百度英翻中〔查看〕
85332查看　85332　在Google字典中的解释Google英翻中〔查看〕
85332查看　85332　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • AnaptysBio
    AnaptysBio, Inc (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today reported financial results for the first quarter ended March 31, 2026, and provided a business update
  • News - AnaptysBio, Inc.
    The Investor Relations website contains information about AnaptysBio, Inc 's business for stockholders, potential investors, and financial analysts
  • Key Catalysts - Anaptys Royalty Co
    Significant upcoming catalysts expected within the next two years 1 Not-exhaustive; 2 Registrational studies also ongoing in China and Japan; 3 HSNCC - Head and neck squamous cell carcinomas; 4 Per clinicaltrials gov estimated primary completion date; 5 GSK Q4 2025 earnings
  • Anaptys Board of Directors Approves Spin-Off of First Tracks . . .
    Board sets spin-off distribution date for First Tracks Biotherapeutics: expected to occur April 20, 2026, pre-market Stockholders will receive one share of First Tracks Bio common stock for every one share of AnaptysBio common stock owned First Tracks Bio initial cash balance of $180 million,
  • Anaptys Provides Update on Business Separation and Announces Fourth . . .
    SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today provided an update on the potential spin-off of its biopharma operations and reported financial results for the fourth quarter and year ended Dec 31, 2025
  • Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or . . .
    SAN DIEGO, Nov 10, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that investigational rosnilimab was safe and well tolerated but did not meet the primary endpoint of mean change from baseline in modified Mayo Score (mMS) or key secondary endpoints of clinical response
  • Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary
    SAN DIEGO , Nov 21, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, announced it has filed a Verified Complaint in Delaware Chancery Court , requesting a court declaration that TESARO, Inc
  • Daniel Faga - Anaptys Royalty Co
    AnaptysBio now exclusively manages the financial collaborations relating to Jemperli with GSK and imsidolimab with Vanda Effective April 20, 2026, Anaptys has spun off its biopharma business, including its therapies, into a new company, First Tracks Biotherapeutics
  • Rosnilimab, a Novel PD-1 Agonist Monoclonal Antibody . . . - AnaptysBio
    Rosnilimab, a Novel PD-1 Agonist Monoclonal Antibody, Reduced T Cell Proliferation, Inflammatory Cytokine Secretion, and PD-1+ Expressing CD4 and CD8 T Cells: Results From a Phase 1 Healthy Volunteer Clinical Trial Kenneth Luu, Martin E Dahl, Eric Hare, Cailin Sibley, Paul Lizzul, Bruce Randazzo AnaptysBio, San Diego, CA, USA





中文字典-英文字典  2005-2009